Intercept Pharmaceuticals, Inc.
ICPT · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $418,374 | $518,966 | $814,359 | $3,922,564 |
| - Cash | $50,517 | $84,709 | $58,151 | $70,055 |
| + Debt | $332,673 | $547,210 | $575,514 | $538,534 |
| Enterprise Value | $700,530 | $981,467 | $1,331,722 | $4,391,043 |
| Revenue | $285,710 | $363,468 | $312,690 | $252,002 |
| % Growth | -21.4% | 16.2% | 24.1% | – |
| Gross Profit | $284,726 | $360,368 | $307,368 | $247,790 |
| % Margin | 99.7% | 99.1% | 98.3% | 98.3% |
| EBITDA | -$61,695 | -$34,852 | -$212,196 | -$294,647 |
| % Margin | -21.6% | -9.6% | -67.9% | -116.9% |
| Net Income | $115,174 | -$145,022 | -$324,230 | -$391,052 |
| % Margin | 40.3% | -39.9% | -103.7% | -155.2% |
| EPS Diluted | 3.4 | -4.55 | -9.83 | -12.35 |
| % Growth | 174.7% | 53.7% | 20.4% | – |
| Operating Cash Flow | -$26,780 | -$41,639 | -$170,026 | -$236,613 |
| Capital Expenditures | -$568 | -$397 | -$3,891 | -$1,136 |
| Free Cash Flow | -$27,348 | -$42,036 | -$173,917 | -$237,749 |